The limits of dermoscopy

Dermoscopy is a powerful adjunct to clinical assessment. It is not a replacement for it. Understanding its limitations makes you a better clinician, not a less confident one.

What dermoscopy cannot see

Dermoscopy visualises structures in the epidermis and superficial dermis. It cannot assess deeper invasion, subcutaneous involvement, or systemic spread. A lesion that looks superficial on dermoscopy may have a deeper component that only histopathology can reveal.

Where dermoscopy is less reliable

Several contexts reduce dermoscopic accuracy:

Amelanotic lesions — as discussed above, reduced pigment means reduced pattern visibility. Vascular patterns may help, but sensitivity for amelanotic melanoma is lower than for pigmented melanoma.

Acral skin — the palms, soles, and nail units have different dermatoscopic patterns from the rest of the body. The TADA algorithm, as taught in this platform, is optimised for non-acral skin. Acral lesions require specific assessment frameworks.

Regressed lesions — a lesion that has partially regressed may show regression structures but may have lost the features that would have identified it as malignant. Dermoscopy sees what is there now, not what was there before.

Small lesions — very small lesions may not display enough structural detail for confident assessment. A 2mm pigmented macule may be too small to show an interpretable pattern.

What dermoscopy does not replace

Dermoscopy does not replace clinical context, patient history, the ugly duckling sign (a clinical observation, not a dermoscopic one), histopathological diagnosis, or specialist assessment when indicated.

It is one tool in your clinical toolkit. A valuable one — but one tool among several.

---